WO2004090113A3 - L53, a lung cancer associated antigen and uses thereof - Google Patents

L53, a lung cancer associated antigen and uses thereof Download PDF

Info

Publication number
WO2004090113A3
WO2004090113A3 PCT/US2004/009951 US2004009951W WO2004090113A3 WO 2004090113 A3 WO2004090113 A3 WO 2004090113A3 US 2004009951 W US2004009951 W US 2004009951W WO 2004090113 A3 WO2004090113 A3 WO 2004090113A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
methods
molecules
genes
acid sequences
Prior art date
Application number
PCT/US2004/009951
Other languages
French (fr)
Other versions
WO2004090113A2 (en
Inventor
Joseph M Petroziello
Charlotte F Mcdonagh
Original Assignee
Seattle Genetics Inc
Joseph M Petroziello
Charlotte F Mcdonagh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc, Joseph M Petroziello, Charlotte F Mcdonagh filed Critical Seattle Genetics Inc
Publication of WO2004090113A2 publication Critical patent/WO2004090113A2/en
Publication of WO2004090113A3 publication Critical patent/WO2004090113A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to L53 genes and gene products that are differentially expressed in cancer tissues and cell lines. In a particular aspect of the invention, L53 genes and gene products are differentially expressed in lung cancer tissues and cell lines. In accordance with the present invention, L53 nucleic acid sequences, amino acid sequences and antibodies thereto, and methods of use thereof are presented. The L53 molecules and methods of the invention may be used to monitor expression levels of L53, wherein the detection of aberrant levels of L53 molecules provides a positive diagnostic indicator of lung cancer and/or other L53 associated cancers and a useful prognostic indice of the state of the diseases. Also provided are compounds capable of modulating L53 activity, which are identified using the L53 molecules and methods of the invention. Such L53 modulating compounds may be used efficaciously to treat patients with lung cancer, or other L53 antigen positive cancers.
PCT/US2004/009951 2003-03-31 2004-03-31 L53, a lung cancer associated antigen and uses thereof WO2004090113A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45922103P 2003-03-31 2003-03-31
US60/459,221 2003-03-31

Publications (2)

Publication Number Publication Date
WO2004090113A2 WO2004090113A2 (en) 2004-10-21
WO2004090113A3 true WO2004090113A3 (en) 2006-06-15

Family

ID=33159628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009951 WO2004090113A2 (en) 2003-03-31 2004-03-31 L53, a lung cancer associated antigen and uses thereof

Country Status (1)

Country Link
WO (1) WO2004090113A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064834A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064834A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
WO2004090113A2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2004110345A3 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2007137187A3 (en) System and method for determining individualized medical intervention for a disease state
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2008118877A3 (en) Method of diagnosing, classifying and treating endometrial cancer and precancer
ATE454468T1 (en) DETECTION OF THE INSTABILITY OF MICROSATELLITES AND USE THEREOF IN TUMOR DIAGNOSIS
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2002022879A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2011082345A3 (en) Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
MXPA03001930A (en) Tnf receptor-like molecules and uses thereof.
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
WO2007071829A3 (en) Methods and means related to diseases
WO2004090113A3 (en) L53, a lung cancer associated antigen and uses thereof
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase